We have injected purified Staphylococcus aureus protein A intraperitoneally into leukemic cats infected with feline leukemia virus, into cats persistently infected with feline leukemia virus but without hematologic or cytologic abnormalities, and into healthy cats without feline leukemia virus infection. Pre-and post-treatment serum samples were evaluated sequentially for interferon activity and for complement-dependent cytotoxic antibody. Our results indicate that serum interferon increased dramatically (<3 to 324 units/ml) during treatment only in cats that responded to staphylococcal protein A therapy. Increase of interferon preceded or was closely associated with increasing levels of cytotoxic antibody, loss of viremia, and correction of cytological and hematological abnormalities of three leukemic cats. The cytotoxic antibody was shown to be specific for envelope glycoprotein gp7O of the feline leukemia virus. One persistently feline leukemia virus-infected cat without leukemia that became nonviremic also developed high levels of interferon and specific cytotoxic antibody. By contrast, interferon levels of cats not responding to treatment had levels of <3 to 27 units/ml. Normal healthy cats injected with staphylococcal protein A showed moderate transient increases of interferon but no detectable cytotoxic antibodies to FL-74 cells. These data suggest that interferon and cytotoxic antibody may play important, possibly complementary roles in inducing remission of leukemia and loss of viremia in cats treated with staphylococcal protein A.
Remission of leukemia-lymphoma associated with disappearance of feline leukemia virus (FeLV) in cats treated by ex vivo immunoadsorption using Staphylococcus aureus Cowan I strain organisms (1, 2) and Staphylococcus protein A (SPA) bound to filters has been reported (2) . The remission of leukemia with either treatment was associated with sustained high levels of a circulating complement-dependent cytotoxic antibody against a feline lymphoma cell line (FL-74) (3) . Using monoclonal antibodies prepared against FeLV and FL-74 cells,t we demonstrated that the cytotoxic antibody was directed against the viral envelope glycoprotein gp7O (3) . In the present report, we show that remission of leukemia and loss of viremia can frequently be induced in cats infected with FeLV with or without leukemia by intraperitoneal (i.p.) injections of SPA. Since SPA induces y interferon (IFNy) in vitro (4, 5) , IFN activity and complementdependent cytotoxic antibody were studied in sera of several cats that had been injected i.p. with SPA. It will be shown that regression of malignancy and loss of evidence of virus infection occurred in cats that experienced first an increase in IFN that was followed by appearance and usually progressive increase of a complement-dependent cytotoxic antibody directed against a virus-infected feline lymphoma cell line.
MATERIAL AND METHODS
Animals. Pet cats were selected for treatment by ex vivo immunoadsorption (2, 3) or by injection with purified SPA (Pharmacia, Uppsala, Sweden). The SPA injections were given i.p. (20 pug/2.75 kg of body weight) twice weekly for 10-12 weeks. Bone marrow and peripheral blood smears were evaluated prior to treatments and after every 10th treatment. FeLV status was determined biweekly by indirect immunofluorescence assay (IFA) (6) and enzyme-linked immunosorbent assay (ELISA) as described (2) . Pre-and posttreatment serum samples were stored at -70'C until assayed for IFN and cytotoxic antibody.
Feline IFN Assay. Feline IFN was assayed by a modification of the microplaque reduction method (7), using approximately 40 plaque-forming units (pfu) of vesicular stomatitis virus (VSV) per well on FFC-9 cells (fetal cat fibroblast cell line kindly provided by N. C. Pedersen, University of California, Davis). An [21] [22] [23] [24] [25] [26] [27] 1983 , Kyoto, Japan (abstr.).
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. tion of feline IFN by NDV, FCC-9 cells were grown in minimal essential medium supplemented with 10% fetal calf serum (GIBCO) and Garamycin (GIBCO) at 40 gg/ml in 75-cm2 plastic flasks (Falcon) until the monolayer became confluent. The culture medium was then replaced by 3 Inhibition of Cytotoxic Activity in Cat Serum. Monoclonal antibodies (MAbs) to FeLV apd FL-74t were used as described (3) in studies of inhibition of cytotoxic antibody. Three of these 'MAbs (7.2,'73.5, and 6.5) were used in the inhibition of cytotoxicity assay as described previously (3).
Inhibition of Cytotoxic Activity in Cat Serum Against FL-74 Cells by Using an F(ab')2 Fragment of Goat Antibody to FeLV gp7O. F(ab')2 fragment of goat antibody to FeLV gp7O was isolated by gel filtration on a Sephadex G-150 (Pharmacia) column (1.5 x 110 cm) as described previously (11) . The F(ab')2 fragment was concentrated and analyzed by NaDod-S04/PAGE and electroblot for molecular weight determination as well as for reactivity with FeLV gp7O in purified FeLV. Inhibition of cytotoxicity assays by using the polyclonal F(ab')2 fragment of anti-FeLV gp7O was performed as described above. fected cats were classified by bone marrow cytology as follows: one cat (152) had frank erythroleukemia,' and three cats (153, 154, 155) were preleukemic. Preleukemia is a synduome characterized by a group of severe hematologic and cytologic abnormalities often associated with anemia, leukopenia, and thrombocytopenia. Some of these animals show a tendency to develop frank leukemia with time (12) .
RESULTS

Responses of Persistently
After treatment with SPA, the following results were obtained. Two cats with preleukemia (153 and 154) and one cat with erythroleukemia (152) went into long-term remission lasting more than 7 months to date. The remissions were characterized by complete correction of the cytological and hematological abnormalities and loss of viremia. Bone marrow before treatment of cats 153 ( Fig. 1 ) and 154 showed erythroid dysplasia, megaloblastosis, and erythroid dyscrasia. These abnormalities were completely corrected after the 10th and'lSth injections of SPA into cats 153 and 154, respectively. Cat 152, which suffered from frank erythroleukemia, went into complete and lasting remission of the leukemia after 20 injections of SPA (Fig. 2) . All cats, including the healthy cats, tolerated the i.p. injections of SPA without fever or hematologic changes (other than the response of the leukemia) or manifestations of ill health. Table 2 . Cat 101 with leukemia (Table 2) , described previously (3), had been successfully treated by ex vivo immunoadsorption using SPA. This cat also developed high levels of serum IFN and was therefore included in this study. As shown, serum IFN from all cats (101, 153, 154, 155) was heat labile (560C/30 min). A pH sensitivity test was performed on serum of cat 101 only, due to shortage of samples, and the IFN was shown to be sensitive. On the other hand, NDV-induced IFN was heat stable, while SEA-induced IFN lost its activity by approximately 60% after pH 2 or heat treatment. These data suggest that the serum IFN produced by these cats during treatment may have properties similar to those observed for SEA-induced IFN and hence likely to be IFNy.
Relationships of gerum IFN and Complement-Dependent
Cytotoxic Antibody, and FeLV Status of Cats Treated with SPA. Fig; 3 shows the relationships of serum IFN, cytotoxic antibody, and FeLV status of four cats (101, 153, 154, 155) that responded to treatment and/or displayed loss of viremia Table 3 . Suppression of cytotoxicity was achieved in a dose-dependent manner when target cells (FL-74) were allowed to incubate with the F(ab')2 fragment from goat antiserum to FeLV gp7O prior to reaction with cytotoxic antibody in cat serum.
DISCUSSION
Prior investigations have shown that, in several malignant diseases of experimental animals (1, 2, 13) or humans (14) (15) (16) , regressions of disease may sometimes be produced by passing blood over columns containing SPA. In our studies ex vivo immunoadsorption with either whole organism Staphylococcus Cowan I protein A or SPA filters produced regressions in approximately 50% of pet cats suffering from FeLV-induced neoplasias. In approximately 18% of virusinfected leukemic cats, viremia also disappeared; 8% had sustained loss of viremia and appeared cured of leukemia (2, 3) . Because leaching of staphylococcal products, SPA, or both was considered a possible mechanism in ex vivo immunoadsorption, the present studies were carried out by using twice-weekly i.p. injections of purified SPA (Pharmacia) z IL.
into FeLV-infected cats with and without leukemia and into healthy cats.
Two of three cats with preleukemia showed dramatic regression, and in one instance there was regression of a frank erythroleukemia. Most of the cats responding to i.p. injection of SPA also lost their viremia. Even in virus-infected cats without leukemia, loss of viremia occurred in one of four. Although definite conclusions are not yet possible, the data reveal that regression of neoplasia and loss of viremia occur in cats that respond with both transient increase of IFN and appearance in the blood of a complement-dependent cytotoxic antibody shown to be specific for envelope glycoprotein gp70 of the virus. The IFN at least in serum of one cat had characteristics of IFNy. Future studies to determine this need to be carried out.
Neither the increased circulating IFN levels nor the cytotoxic antibodies appeared in healthy uninfected cats treated with SPA or cats that were nonresponsive to the SPA injections and maintained leukemia, viremia, or both in spite of the treatment. Just what role the IFN response plays in regression of the neoplastic disease and the virus infection and how its influence relates to the role of the cytotoxic antibody is unclear. Nonetheless, it is provocative to consider several properties of IFN that may be playing a role-i.e., its antiproliferative influences (17, 18) , its capacity to activate macrophages and other effector cells (19, 20) that can inhibit neoplasia, and its increase of natural killer functions (21) . Each of these possibilities needs investigation in future analyses. One of the most provocative aspects of the present investigations is that, once the neoplasms have regressed and a viral negative state has been achieved, the disease often to date has not recurred. This might be attributable to the antiviral or antitumor actions of the cytotoxic antibody or to both. These mechanisms, of course, would not exclude other mechanisms involving the cell-mediated immunities, which have not yet been studied.
